Quality of life in ovarian cancer patients choosing to receive salvage chemotherapy or palliative treatment

12Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

Abstract

Background: The hypothesis that patients who primarily progress on two consecutive chemotherapy regimens without evidence of clinical benefit may opt for supportive care was investigated. The purpose was to determine the quality of life in recurrent ovarian cancer patients choosing to receive salvage chemotherapy in addition to supportive care or palliative care alone. A secondary objective was to evaluate factors that affect quality of life in ovarian cancer patients. Materials and Methods: A descriptive study was conducted in patients who had histological confirmed epithelial ovarian cancer and failed to respond to at least one regimen of chemotherapy, coming for treatment at the King Chulalongkorn Memorial Hospital in Bangkok, Thailand over a six-month period from August 2012-March 2013. Each patient was asked to complete the FACT-G and a general personal questionnaire. The median quality of life score was analyzed. The Mann Whitney U Test was used to compare the difference between salvage chemotherapy and palliative care groups, and the Kruskal Wallis was used to evaluate other variables. Results: Thirty-eight ovarian cancer patients were identified who failed to respond to chemotherapy. Of the 38, 30 chose salvage chemotherapy and eight palliative care for further treatment. By histology the carcimnomas were predominantly endometrioid subtype and poorly differentiated. The majority of patients in this study had FIGO stage III, and ECOG status 0-1. The median quality of life score was 76.3 (35.8-94.0), with no significant differences between the groups. Factors associated with the quality of life were the ECOG score and number of chemotherapeutic courses. Conclusions: In the setting of refractory or recurrent epithelial ovarian cancer, patients who receive salvage chemotherapy have comparable quality of life scores with patients treated with palliative care alone, providing a contrast with previous studies.

References Powered by Scopus

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

385Citations
N/AReaders
Get full text

Depression, anxiety, and quality of life in patients with epithelial ovarian cancer

275Citations
N/AReaders
Get full text

Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer

172Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Coping and quality of life in Turkish women living with ovarian cancer

32Citations
N/AReaders
Get full text

Phytoestrogen intake and risk of ovarian cancer: A meta-analysis of 10 observational studies

31Citations
N/AReaders
Get full text

Social support and quality of life in Turkish patients with gynecologic cancer

17Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Srisuttayasathien, M., & Khemapech, N. (2013). Quality of life in ovarian cancer patients choosing to receive salvage chemotherapy or palliative treatment. Asian Pacific Journal of Cancer Prevention, 14(12), 7669–7674. https://doi.org/10.7314/APJCP.2013.14.12.7669

Readers over time

‘14‘15‘16‘17‘18‘19‘20‘21‘22‘23‘2402468

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 8

67%

Researcher 4

33%

Readers' Discipline

Tooltip

Medicine and Dentistry 15

68%

Nursing and Health Professions 4

18%

Psychology 2

9%

Sports and Recreations 1

5%

Save time finding and organizing research with Mendeley

Sign up for free
0